QMS Medical

Which are the latest news on QMS Medical?

Why is QMS Medical Allied Services Ltd falling/rising?

As of 05-Sep, QMS Medical Allied Services Ltd's stock price is slightly down at 158.97, but it has shown strong performance with a 77.42% year-to-date increase. Despite this, a 39.1% decline in profits and trading at a premium compared to peers may be causing cautious investor sentiment.

As of 05-Sep, QMS Medical Allied Services Ltd is experiencing a slight decline in its stock price, currently at 158.97, down by 0.1 or 0.06%. Despite this minor drop, the stock has shown strong performance over various time periods, including a 4.66% increase over the past week and a remarkable 38.36% rise over the past month. Year-to-date, the stock has surged by 77.42%, significantly outperforming the broader market, which has seen an 8.54% decline.<BR><BR>The stock is currently trading close to its 52-week high, just 3.6% away from Rs 164.7, and it has outperformed its sector by 3.48% today. Additionally, QMS Medical is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in its price movements.<BR><BR>However, it is important to note that while the stock has generated substantial returns over the past year, its profits have decreased by 39.1%. This decline in profitability, coupled with the stock trading at a premium compared to its peers' average historical valuations, may contribute to the cautious sentiment among investors, leading to the current slight decline in price. Overall, despite the recent drop, the stock's strong historical performance and market-beating returns suggest a complex picture of investor sentiment.

Who are in the management team of QMS Medical?

The management team of QMS Medical includes Mahesh Makhija (Chairperson & Managing Director), Diti Makhija (Non-Executive Director), Guddi Makhija (Whole-time Director), Gautam Khanna and Raju Bhatia (Non-Executive Independent Directors), and Deepali Malpani (Company Secretary & Compliance Officer). They are responsible for the company's strategic direction and regulatory compliance.

The management team of QMS Medical includes the following individuals:<BR><BR>1. **Mahesh Makhija** - Chairperson & Managing Director<BR>2. **Diti Makhija** - Non-Executive & Non-Independent Director<BR>3. **Guddi Makhija** - Whole-time Director<BR>4. **Gautam Khanna** - Non-Executive & Independent Director<BR>5. **Raju Bhatia** - Non-Executive & Independent Director<BR>6. **Deepali Malpani** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory requirements.

What does QMS Medical do?

QMS Medical Allied Services Ltd markets and distributes a variety of medical products and equipment in the healthcare sector. As of June 2026, it reported net sales of 57 Cr and a net profit of 4 Cr, with a market cap of INR 301 Cr.

Overview:<BR>QMS Medical Allied Services Ltd is engaged in the marketing, trading, and distribution of a wide range of medical products, instruments, equipment, and devices within the healthcare services industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated as 'QMS Medical Allied Services Private Limited' in 2017 and changed its status to a public limited company on October 22, 2020. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 57 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 301 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.33% <BR>Debt-Equity: 0.58 <BR>Return on Equity: 9.63% <BR>Price to Book: 2.82 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the QMS Medical?

QMS Medical's peers include Nureca, Take, Bilcare, Prevest Denpro, Hemant Surgical, and Star Imaging. QMS Medical has an average management risk and a 1-year return of 76.94%, outperforming its peers.

Peers: The peers of QMS Medical are Nureca, Take, Bilcare, Prevest Denpro, Hemant Surgical, and Star Imaging.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro and Star Imaging, while Average management risk is found at QMS Medical and Hemant Surgical, and Below Average management risk is seen at Nureca, Take, and Bilcare. Growth is rated as Good for Bilcare and Hemant Surgical, Average for QMS Medical, and Below Average for Nureca, Take, Prevest Denpro, and Star Imaging. Capital Structure is rated as Excellent for Prevest Denpro, Good for Nureca and Hemant Surgical, and Average for QMS Medical, while Below Average is noted for Take and Bilcare.<BR><BR>Return Snapshot: QMS Medical has a 1-year return of 76.94%, which is higher than Nureca's 38.19%, the highest among peers, and significantly higher than Take's -61.76%, the lowest. Additionally, Prevest Denpro, Hemant Surgical, and Star Imaging have a six-month return of 0.00%.

How big is QMS Medical?

As of 31st August, QMS Medical Allied Services Ltd has a market capitalization of 301.00 Cr, with recent net sales of 183.25 Cr and a net profit of 10.75 Cr.

As of 31st August, QMS Medical Allied Services Ltd has a market capitalization of 301.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, QMS Medical reported Net Sales of 183.25 Cr and a Net Profit of 10.75 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 89.71 Cr and Total Assets of 189.79 Cr.

Should I buy, sell or hold QMS Medical Allied Services Ltd?

Are QMS Medical Allied Services Ltd latest results good or bad?

QMS Medical Allied Services Ltd's latest results are concerning, showing a 48.50% decline in net profit year-on-year and a drop in operating margin to 12.97%. Despite a slight recovery in net sales, the overall financial health is deteriorating due to rising costs and interest expenses, leading to negative investor sentiment.

The latest results for QMS Medical Allied Services Ltd indicate a challenging financial performance. In Q4 FY26, the company reported a consolidated net profit of ₹1.72 crores, which represents a significant decline of 48.50% year-on-year and a decrease of 28.33% quarter-on-quarter. This sharp drop in profitability is concerning, especially given that the operating margin fell to 12.97%, the lowest in eight quarters, down from 19.49% in the same quarter last year.<BR><BR>While net sales showed a slight recovery with a 19.22% increase compared to the previous quarter, they still experienced a marginal decline of 0.36% year-on-year. This suggests that despite a sequential improvement in revenue, the overall financial health of the company is deteriorating, primarily due to rising operational costs and significant interest expenses.<BR><BR>The return on equity has also dropped to 10.20%, which is below industry standards, raising further concerns about the company's efficiency and profitability. The stock has reacted negatively to these results, declining by 0.57% post-announcement, reflecting investor disappointment.<BR><BR>Overall, the results can be characterized as bad, highlighting serious issues with profitability, margin compression, and rising debt levels, which pose significant risks to the company's future performance.

How has been the historical performance of QMS Medical?

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 156.01 Cr and profit after tax increasing to 13.70 Cr. The company also saw improvements in operating profit and cash flow from operating activities, despite a decline in cash flow from investing activities.

Answer:<BR>The historical performance of QMS Medical shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, QMS Medical reported net sales of 156.01 Cr, an increase from 122.13 Cr in the previous year. Total operating income also rose to 156.01 Cr from 122.13 Cr, while total expenditure increased to 130.60 Cr from 103.78 Cr. The operating profit (PBDIT) excluding other income improved to 25.41 Cr from 18.35 Cr, leading to an overall operating profit of 27.13 Cr compared to 18.81 Cr in the prior year. Profit before tax saw a rise to 18.66 Cr from 12.24 Cr, and profit after tax increased to 13.70 Cr from 9.00 Cr. The earnings per share (EPS) grew to 6.7 from 5.04. On the balance sheet, total assets increased to 189.79 Cr from 135.32 Cr, with total liabilities also rising to 189.79 Cr from 135.32 Cr. Cash flow from operating activities significantly improved to 20.00 Cr from 1.00 Cr, while cash flow from investing activities worsened to -45.00 Cr from -2.00 Cr. Overall, QMS Medical demonstrated a positive trend in revenue and profitability, alongside a notable increase in total assets and liabilities.

Is QMS Medical overvalued or undervalued?

As of August 14, 2025, QMS Medical is considered an attractive investment due to its undervalued status with a PE ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, especially when compared to higher valuations of peers like Poly Medicure and Blue Jet Health, despite a year-to-date stock decline of 33.85% against the Sensex's gain of 4.17%.

As of 14 August 2025, QMS Medical's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, suggesting that it is trading at a discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, QMS Medical stands out as more reasonably priced. For example, Poly Medicure has a PE ratio of 53.86, while Blue Jet Health is at 38.33, both of which are significantly higher than QMS Medical's valuation. Additionally, the company's return on capital employed (ROCE) is 13.06%, which further supports its attractiveness in the healthcare services industry. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 33.85% compared to the Sensex's gain of 4.17%, the underlying valuation metrics suggest that QMS Medical presents a compelling investment opportunity.

Who are the top shareholders of the QMS Medical?

The top shareholders of QMS Medical include Mahesh Pahalraj Makhija with 71.98%, individual investors with 22.95%, and a foreign institutional investor holding 0.01%. There are no mutual funds invested, and no pledged promoter holdings indicate strong promoter commitment.

The top shareholders of QMS Medical primarily include the promoters, with Mahesh Pahalraj Makhija holding the largest share at 71.98%. Additionally, individual investors collectively hold 22.95% of the shares. There is one foreign institutional investor (FII) that holds a small portion of 0.01%, but there are no mutual funds currently invested in the company. There are no pledged promoter holdings, indicating a strong commitment from the promoters.

What is the technical trend for QMS Medical?

As of May 16, 2025, QMS Medical's technical trend is mildly bearish, with bearish daily moving averages and mixed signals from MACD and Dow Theory, despite a mildly bullish weekly MACD.

As of 16 May 2025, the technical trend for QMS Medical has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages are bearish. The Bollinger Bands and KST both show bearish signals on the weekly timeframe. The Dow Theory suggests a mildly bullish trend on the weekly, but the overall indicators lean towards a bearish sentiment. The OBV is mildly bearish on the weekly and monthly. Overall, the current technical stance is mildly bearish, with key indicators being the bearish moving averages and the mixed signals from MACD and Dow Theory.

When is the next results date for QMS Medical?

No Upcoming Board Meetings

Has QMS Medical declared dividend?

QMS Medical Allied Services Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating financial challenges despite the dividend announcement.

QMS Medical Allied Services Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.58%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.57%, the dividend return was 0%, resulting in a total return of -22.57%.<BR><BR>Over the past year, the price return was -11.98%, the dividend return was 0.47%, leading to a total return of -11.51%.<BR><BR>For the 2-year period, the price return was -28.34%, the dividend return was 0.65%, which resulted in a total return of -27.69%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and the total return remained at 0.0%.<BR><BR>For the 4-year period, there was also no price return, no dividend return, and the total return stayed at 0.0%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and the total return was 0.0%.<BR><BR>Overall, while QMS Medical has declared a dividend, the total returns over various periods indicate negative performance, particularly in the short and medium term, suggesting challenges in the company's financial performance despite the dividend announcement.